Galapagos is a drug discovery company with two operating divisions: drug discovery and BioFocus DPI, Galapagos’ service division. Galapagos’ drug discovery division aims to develop novel, disease-modifying drugs in selected bone and joint disease areas for which there is a need for safe and effective medicines. Galapagos’ BioFocus DPI service division offers a full suite of target-to-candidate drug discovery products and services to pharmaceutical and biotech companies as well as to not-for-profit organizations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

August 26, 2008
Galapagos acquires structure-based drug discovery from Sareum
Read more

August 12, 2008
UCB transfers UK-based medicinal chemistry program to BioFocus DPI

Read more

August 8, 2008
Strong revenue growth and sharp improvement of net result for Galapagos in 1H 2008
View webcast here
Read more

Disclaimer
© Copyright 2008 Galapagos NV